David Salazar, MD
Critical Care (Intensivists) · San Antonio, TXNPI 1104810910
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (44.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Intuitive Surgical at 53.2% of the total. 2025 is the largest year on record at $5,174, 3.0 times the $1,728 reported in 2019. Among critical care (intensivists) clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $42.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$599
- Grifols USA, LLC$518
- Boehringer Ingelheim$490
- Edwards Lifesciences$469
- plus $1K from 19 others
What the payments were for
- Travel & lodging$1,13512%
- Food & beverage$4,09644%
- Education$4,16944%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $5,002 |
| Actelion Pharmaceuticals US, Inc. | 47 | $1,026 |
| GSK | 48 | $599 |
| Grifols USA, LLC | 22 | $518 |
| Boehringer Ingelheim | 20 | $490 |
| Edwards Lifesciences | 2 | $469 |
| Johnson & Johnson | 18 | $269 |
| Mylan Specialty L.p. | 8 | $165 |
| Regeneron Healthcare Solutions, Inc. | 4 | $124 |
| AstraZeneca | 8 | $122 |
| Gilead | 5 | $111 |
| Galvanize Therapeutics, Inc | 1 | $101 |
| Philips North America LLC | 5 | $81 |
| Genentech USA, Inc. | 4 | $62 |
| Circassia Inc. | 3 | $46 |
| Sanofi | 2 | $44 |
| Verona Pharma, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,400 in reported general payments places this provider in the 95th percentile of 22 critical care (intensivists) providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $318,692 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $114,617 |
| Dupixent PenDupilumab | 12 | $43,265 |
| XolairOmalizumab | 12 | $33,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $27,667 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $12,819 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,950 |
| Pirfenidone | 11 | $8,386 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,233 |
| Roflumilast | 34 | $3,349 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,161 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,088 |
| Azithromycin | 17 | $339 |
| Montelukast Sodium | 18 | $97 |
| Prednisone | 25 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $490 | $331,51137 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $599 | $131,799126 claims |
| AstraZenecaBreztri Aerosphere | $122 | $27,66731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 critical care (intensivists) providers in Texas.
Other critical care (intensivists) in San Antonio
- Alexandra MariSan Antonio$0
- Ahmad AltarawnehSan Antonio$0
- Jeffrey LillyPlano$0
- Muhammad MalikHouston$0
- Kimber FoustDallas$0
- Maria GaetaHouston$0
- Yunuen Aguilera GarciaHouston$0
- Francis AmedeHouston$0
- Wylan PetersonFort Sam Houston$0
- Lavi OudOdessa$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.